All In MedTech

Device Trial Radar · NCT05058430

SaliPen Human Factors Study for OTC Labeling

Last checked: Nov 20, 2026Latest source record: Jan 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Sep 16, 2021

Primary completion

Nov 18, 2021

Study completion Nov 18, 2021

Sponsor

Lead sponsor
Saliwell Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
Indiana University
First posted
Sep 27, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Human Factors Validation Testing will assess user interactions to verify the capability of potential users to assess if the study product fits their needs and if they can use it correctly based on the provided Information For User (IFU)? More specifically, this is a non-comparative case series study and is subdivided into two major parts. Those parts are: 1. Phase I: aimed at testing if, based on the IFU, the potential subjects can decide whether the study product is or is not appropriate to treat their condition and, 2. Phase II: aimed at assessing whether the users can use the study product correctly without counseling by a health care provider.

Conditions

  • Xerostomia

Interventions

  • Electrical salivary stimulator system assigned to subjects with xerostomiaDevice

    SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).

  • No Electrical salivary stimulator system assigned to subjects without xerostomiaDevice

    SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Appropriately Will Self-select the Study Product for Use Under Simulated OTC Conditions [Phase I]Time frame: One hour

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Indiana University School of Dentistry, Oral Health Research Institute

    Indianapolis, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.